Harrow, Inc. (HROW) stock analysis
HROW · Harrow, Inc.
Latest recorded price: USD 29.09
Model-estimated fair value: USD 3.11. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic
At $29.09, HROW trades 836.4% above the model's base-case value of $3.11. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $0.86 in the conservative case and $5.84 in the optimistic case, with a valuation confidence score of 65/100. About 75% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 45.4%, free cash flow margin 15.8%, ROIC 8.9%. The model flags 1 risk signal for this company.
Similar companies in Healthcare
- Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA)
- Lantheus Holdings, Inc. (LNTH)
- Liquidia Corporation (LQDA)
- Neurocrine Biosciences, Inc. - Common Stock (NBIX)
- Phibro Animal Health Corporation (PAHC)
- Prestige Consumer Healthcare Inc. (PBH)
- Pacira BioSciences, Inc. (PCRX)
- Perrigo Company plc (PRGO)